Modeling ALS with Patient-Derived iPSCs: Recent Advances and Future Potentials.

Area of Science:

• Neuroscience
• Stem Cell Biology
• Drug Discovery

Background:

• Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder with limited preclinical models, especially for sporadic cases.
• Current limitations in animal and in vitro models hinder the development of effective treatments for ALS.
• Human-derived induced pluripotent stem cell (hiPSC) technology presents a promising avenue for disease modeling.

Purpose of the Study:

• To review recent advancements in hiPSC-derived models for studying ALS.
• To evaluate the progress of 2D monocultures, co-cultures, and 3D organoids in ALS research.
• To highlight the potential of hiPSC models for preclinical drug screening in ALS.

Main Methods:

• Review of current literature on hiPSC-derived neuronal and non-neuronal models for ALS.
• Analysis of 2D monoculture, co-culture, and 3D organoid systems.
• Examination of applications in preclinical drug discovery for ALS.

Main Results:

• hiPSC technology enables the creation of diverse and relevant cell types for ALS modeling.
• Progress has been made in developing 2D and 3D in vitro models using hiPSCs.
• These models show significant potential for advancing preclinical drug studies in ALS.

Conclusions:

• hiPSC-derived models are invaluable tools for understanding ALS pathogenesis.
• Despite challenges, hiPSC models offer vast opportunities for preclinical drug screening and development.
• Further research into hiPSC-based models is essential for accelerating ALS treatment discovery.